Article in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors at 6 institutions in 2 countries.
Olaia Lucas-JiménezDepartment of Psychology, Faculty of Health Sciences, University of Deusto, 48007 Bilbao, Spain.ORCID 0000-0002-7715-3764
Naroa Ibarretxe-BilbaoDepartment of Psychology, Faculty of Health Sciences, University of Deusto, 48007 Bilbao, Spain.ORCID 0000-0002-2434-5252
Ibai DiezGordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114-1107, USA.
Javier PeñaDepartment of Psychology, Faculty of Health Sciences, University of Deusto, 48007 Bilbao, Spain.
Beatriz TijeroNeurodegenerative Diseases Group, Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.
Marta GaldósOphthalmology Department, Cruces University Hospital, 48903 Barakaldo, Spain.
Ane Murueta-GoyenaNeurodegenerative Diseases Group, Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.ORCID 0000-0002-9808-6943
Rocío Del PinoNeurodegenerative Diseases Group, Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.ORCID 0000-0002-6612-4757
Marian AceraNeurodegenerative Diseases Group, Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.
Juan Carlos Gómez-EstebanNeurodegenerative Diseases Group, Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.
Iñigo GabilondoNeurodegenerative Diseases Group, Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.ORCID 0000-0001-6045-2840
Natalia OjedaDepartment of Psychology, Faculty of Health Sciences, University of Deusto, 48007 Bilbao, Spain.ORCID 0000-0002-0952-0649
Universidad de Deusto · ESBioCruces Health research Institute · ESUniversity of the Basque Country · ESHarvard University · USHospital de Cruces · ESIkerbasque · ES
Funding
Instituto de Salud Carlos III PI14/00679Juan Rodes (Co-funded by European Regional Development Fund/European Social Fund - "Investing in your future"). JR15/00008Michael J. Fox Foundation RRIA 2014 (Rapid Response Innovation Awards) Program 10189
6 · The paper itself
Abstract
backgroundWe aimed to characterize subtypes of synucleinopathies using a clustering approach based on cognitive and other nonmotor data and to explore structural and functional magnetic resonance imaging (MRI) brain differences between identified clusters.
methodsSixty-two patients (
resultsHCA revealed two subtypes, the mild subtype (
conclusionsThese findings support the potential value of incorporating an extensive nonmotor evaluation to characterize specific clinical patterns and brain degeneration patterns of synucleinopathies.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Brain Degeneration in Synucleinopathies Based on Analysis of Cognition and Other Nonmotor Features: A Multimodal Imaging Study. · full record | OpenQuestion